{"id":4206,"date":"2018-03-25T14:34:46","date_gmt":"2018-03-25T12:34:46","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/medikament-gegen-chronisch-entzuendliche-darmerkrankungen\/"},"modified":"2020-06-29T14:24:56","modified_gmt":"2020-06-29T12:24:56","slug":"medikament-gegen-chronisch-entzuendliche-darmerkrankungen","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/medikament-gegen-chronisch-entzuendliche-darmerkrankungen\/","title":{"rendered":"Immunic develops successfully drug for inflammatory bowel disease"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Immunic develops successfully drug for inflammatory bowel disease<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]Planned Phase 2 \u00adtrial in patients allowed to start[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]March 2018[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”4201″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Immunic AG[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]IMU-838 is an orally available, next-generation selective immune modulator. IMU-838 targets intracellular metabolism of activated immune cells by inhibition of the enzyme \u201cdihydroorotate dehydrogenase\u201d (DHODH). With this mode of action, IMU-838 is a potent inhibitor of Th17 and Th1 subsets of T-lymphocytes as well as activated B-cells without potentially increasing the risk of viral infections.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Immunic AG announced that it has received communication from the US Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for its oral investigational drug IMU-838. This will allow Immunic to initiate the Phase 2 trial in patients with ulcerative colitis (UC). This IND approval marks a significant milestone for Immunic. This clinical trial (CALDOSE-1) is the first Phase 2 trial as part of the global development plan with the goal to demonstrate clinical efficacy of IMU-838 for inflammatory bowel disease (IBD). \u201cWe are very pleased receiving the swift IND approval from the FDA. This will accelerate our development of IMU-838 as a promising candidate for therapies of chronic inflammatory bowel diseases\u201d, says Dr. Daniel Vitt, CEO of Immunic. \u201cThis step underlines that we\u2019re progressing well on our way to deliver a phase III ready product in due time.\u201d Dr. Andreas M\u00fchler, Chief Medical Officer of Immunic adds: \u201cThe FDA\u2019s approval of our IND application is a big milestone in developing our selective immune modulator IMU-838 into a globally available drug for the treatment of IBD.\u201d[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n